Membrane-anchored proteases in endothelial cell biology

Current Opinion in Hematology

Volumn 23, Issue 3, 2016, Pages 243-252

  Antalis, Toni M ^a   Conway, Gregory D ^a   Peroutka, Raymond J ^a   Buzza, Marguerite S ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

ADAM; Angiotensin converting enzyme; Membrane tethered matrix metalloprotease; Membrane anchored serine protease; Pro protein convertase

Indexed keywords

MEMBRANE ANCHORED PROTEASE; PEPTIDE; PROTEIN TYROSINE KINASE; PROTEINASE; UNCLASSIFIED DRUG; SERINE PROTEINASE;

BLOOD VESSEL PERMEABILITY; CELL SURFACE; CYTOLOGY; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; LIPID RAFT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; TRANSACTIVATION; VASCULAR BIOLOGY; CELL MEMBRANE; ENZYMOLOGY; METABOLISM; PHYSIOLOGY;

CELL MEMBRANE; ENDOTHELIAL CELLS; HUMANS; SERINE ENDOPEPTIDASES;

EID: 84959115305     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000238     Document Type: Review

References (99)

1. Favero G, Paganelli C, Buffoli B, et al. Endothelium and its alterations in cardiovascular diseases: life style intervention. Biomed Res Int 2014; 2014:801896.
2. Kitamura K, Tomita K. Proteolytic activation of the epithelial sodium channel and therapeutic application of a serine protease inhibitor for the treatment of salt-sensitive hypertension. Clin Exp Nephrol 2012; 16:44-48.
3. Maekawa A, Kakizoe Y, Miyoshi T, et al. Camostat mesilate inhibits prostasin activity and reduces blood pressure and renal injury in salt-sensitive hypertension. J Hypertens 2009; 27:181-189.
4. Zhu H, Guo D, Li K, et al. Prostasin: a possible candidate gene for human hypertension. Am J Hypertens 2008; 21:1028-1033.
5. Frateschi S, Keppner A, Malsure S, et al. Mutations of the serine protease CAP1/Prss8 lead to reduced embryonic viability, skin defects, and decreased ENaC activity. Am J Pathol 2012; 181:605-615.
6. Planes C, Randrianarison NH, Charles RP, et al. ENaC-mediated alveolar fluid clearance and lung fluid balance depend on the channel-activating protease 1. EMBO Mol Med 2010; 2:26-37.
7. Leyvraz C, Charles RP, Rubera I, et al. The epidermal barrier function is dependent on the serine protease CAP1/Prss8. J Cell Biol 2005; 170:487-496.
8. Uchimura K, Hayata M, Mizumoto T, et al. The serine protease prostasin regulates hepatic insulin sensitivity by modulating TLR4 signalling. Nat Commun 2014; 5:3428.
9. Buzza MS, Netzel-Arnett S, Shea-Donohue T, et al. Membrane-anchored serine protease matriptase regulates epithelial barrier formation and permeability in the intestine. Proc Natl Acad Sci U S A 2010; 107:4200-4205.
10. Szabo R, Rasmussen AL, Moyer AB, et al. c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase. Oncogene 2011; 30:2003-2016.
11. List K, Kosa P, Szabo R, et al. Epithelial integrity is maintained by a matriptasedependent proteolytic pathway. Am J Pathol 2009; 175:1453-1463.
12. Wang CY, Meynard D, Lin HY. The role of TMPRSS6/matriptase-2 in iron regulation and anemia. Front Pharmacol 2014; 5:114.
13. Webb SL, Sanders AJ, Mason MD, Jiang WG. Matriptase-2 inhibits HECV motility and tubule formation in vitro and tumour angiogenesis in vivo. Mol Cell Biochem 2013; 375:207-217.
14. Armaly Z, Assady S, Abassi Z. Corin: a new player in the regulation of saltwater balance and blood pressure. Curr Opin Nephrol Hypertens 2013; 22:713-722.
15. Zhou Y, Wu Q. Corin in natriuretic peptide processing and hypertension. Curr Hypertens Rep 2014; 16:415.
16. Cui Y, Wang W, Dong N, et al. Role of corin in trophoblast invasion and uterine spiral artery remodelling in pregnancy. Nature 2012; 484:246-250.
17. Roebroek AJ, Umans L, Pauli IG, et al. Failure of ventral closure and axial rotation in embryos lacking the proprotein convertase Furin. Development 1998; 125:4863-4876.
18. Kim W, Essalmani R, Szumska D, et al. Loss of endothelial furin leads to cardiac malformation and early postnatal death. Mol Cell Biol 2012; 32:3382-3391.
19. Solun B, Marcoviciu D, Dicker D. Dipeptidyl peptidase-4 inhibitors and their effects on the cardiovascular system. Curr Cardiol Rep 2013; 15:382.
20. Zhong J, Rajagopalan S. Dipeptidyl peptidase-4 regulation of SDF-1/CXCR4 axis: implications for cardiovascular disease. Front Immunol 2015; 6:477.
21. Sauve M, Ban K, Momen MA, et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 2010; 59:1063-1073.
22. Pacheco BP, Crajoinas RO, Couto GK, et al. Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. J Hypertens 2011; 29:520-528.
23. van Hinsbergh VW, Koolwijk P. Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc Res 2008; 78:203-212.
24. van Hinsbergh VW, Engelse MA, Quax PH. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol 2006; 26:716-728.
25. Chen Q, Jin M, Yang F, et al. Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediators Inflamm 2013; 2013:928315.
26. Martin-Alonso M, Garcia-Redondo AB, Guo D, et al. Deficiency of MMP17/MT4-MMP proteolytic activity predisposes to aortic aneurysm in mice. Circ Res 2015; 117:e13-e26.
27. Dreymueller D, Pruessmeyer J, Groth E, Ludwig A. The role of ADAMmediated shedding in vascular biology. Eur J Cell Biol 2012; 91:472-485.
28. Guaiquil VH, Swendeman S, Zhou W, et al. ADAM8 is a negative regulator of retinal neovascularization and of the growth of heterotopically injected tumor cells in mice. J Mol Med (Berl) 2010; 88:497-505.
29. Romagnoli M, Mineva ND, Polmear M, et al. ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis. EMBO Mol Med 2014; 6:278-294.
30. Guaiquil V, Swendeman S, Yoshida T, et al. ADAM9 is involved in pathological retinal neovascularization. Mol Cell Biol 2009; 29:2694-2703.
31. Glomski K, Monette S, Manova K, et al. Deletion of Adam10 in endothelial cells leads to defects in organ-specific vascular structures. Blood 2011; 118:1163-1174.
32. Caolo V, Swennen G, Chalaris A, et al. ADAM10 and ADAM17 have opposite roles during sprouting angiogenesis. Angiogenesis 2015; 18:13-22.
33. Dokun AO, Chen L, Okutsu M, et al. ADAM12: a genetic modifier of preclinical peripheral arterial disease. Am J Physiol Heart Circ Physiol 2015; 309:H790-H803.
34. Cui D, Arima M, Takubo K, et al. ADAM12 and ADAM17 are essential molecules for hypoxia-induced impairment of neural vascular barrier function. Sci Rep 2015; 5:12796.
35. Sun C, Wu MH, Lee ES, Yuan SY. A disintegrin and metalloproteinase 15 contributes to atherosclerosis by mediating endothelial barrier dysfunction via Src family kinase activity. Arterioscler Thromb Vasc Biol 2012; 32:2444-2451.
36. Sun C, Beard RS Jr, McLean DL, et al. ADAM15 deficiency attenuates pulmonary hyperpermeability and acute lung injury in lipopolysaccharide-treated mice. Am J Physiol Lung Cell Mol Physiol 2013; 304:L135-L142.
37. Maretzky T, Blobel CP, Guaiquil V. Characterization of oxygen-induced retinopathy in mice carrying an inactivating point mutation in the catalytic site of ADAM15. Invest Ophthalmol Vis Sci 2014; 55:6774-6782.
38. Weskamp G, Mendelson K, Swendeman S, et al. Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes. Circ Res 2010; 106:932-940.
39. Holloway JW, Laxton RC, Rose-Zerilli MJ, et al. ADAM33 expression in atherosclerotic lesions and relationship of ADAM33 gene variation with atherosclerosis. Atherosclerosis 2010; 211:224-230.
40. Holgate ST, Yang Y, Haitchi HM, et al. The genetics of asthma: ADAM33 as an example of a susceptibility gene. Proc Am Thorac Soc 2006; 3:440-443.
41. Puxeddu I, Pang YY, Harvey A, et al. The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma. J Allergy Clin Immunol 2008; 121:1400-1406.
42. Te RL, van Esch JH, Roks AJ, et al. Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res 2015; 116:960-975.
43. Robles NR, Cerezo I, Hernandez-Gallego R. Renin-angiotensin system blocking drugs. J Cardiovasc Pharmacol Ther 2014; 19:14-33.
44. Mendoza-Torres E, Oyarzun A, Mondaca-Ruff D, et al. ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension. Ther Adv Cardiovasc Dis 2015; 9:217-237.
45. Ferrao FM, Lara LS, Lowe J. Renin-angiotensin system in the kidney: what is new? World J Nephrol 2014; 3:64-76.
46. Bugge TH, Antalis TM, Wu Q. Type II transmembrane serine proteases. J Biol Chem 2009; 284:23177-23181.
47. Itoh Y. Membrane-type matrix metalloproteinases: their functions and regulations. Matrix Biol 2015; 44-46:207-223.
48. Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003; 17:7-30.
49. Antalis TM, Bugge TH, Wu Q. Membrane-anchored serine proteases in health and disease. Prog Mol Biol Transl Sci 2011; 99:1-50.
50. Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 2002; 3:753-766.
51. Gass J, Khosla C. Prolyl endopeptidases. Cell Mol Life Sci 2007; 64:345-355.
52. Tikellis C, Thomas MC. Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. Int J Pept 2012; 2012:256294.
53. Lee HS, Park BM, Cho Y, et al. Shedding of epithin/PRSS14 is induced by TGF-beta and mediated by tumor necrosis factor-alpha converting enzyme. Biochem Biophys Res Commun 2014; 452:1084-1090.
54. Antalis TM, Buzza MS, Hodge KM, et al. The cutting edge: membraneanchored serine protease activities in the pericellular microenvironment. Biochem J 2010; 428:325-346.
55. Yana I, Weiss SJ. Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases. Mol Biol Cell 2000; 11:2387-2401.
56. Ghajar CM, George SC, Putnam AJ. Matrix metalloproteinase control of capillary morphogenesis. Crit Rev Eukaryot Gene Expr 2008; 18:251-278.
57. Wong E, Maretzky T, Peleg Y, et al. The functional maturation of A Disintegrin and Metalloproteinase (ADAM) 9, 10, and 17 requires processing at a newly identified proprotein convertase (PC) cleavage site. J Biol Chem 2015; 290:12135-12146.
58. Maney SK, McIlwain DR, Polz R, et al. Deletions in the cytoplasmic domain of iRhom1 and iRhom2 promote shedding of the TNF receptor by the protease ADAM17. Sci Signal 2015; 8:ra109.
59. Friis S, Uzzun SK, Godiksen S, et al. A matriptase-prostasin reciprocal zymogen activation complex with unique features: prostasin as a nonenzymatic co-factor for matriptase activation. J Biol Chem 2013; 288:19028-19039.
60. Peters DE, Szabo R, Friis S, et al. The membrane-anchored serine protease prostasin (CAP1/PRSS8) supports epidermal development and postnatal homeostasis independent of its enzymatic activity. J Biol Chem 2014; 289:14740-14749.
61. Blobel CP. ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol 2005; 6:32-43.
62. Weber S, Saftig P. Ectodomain shedding and ADAMs in development. Development 2012; 139:3693-3709.
63. Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer 2008; 8:929-941.
64. Murphy G. Regulation of the proteolytic disintegrin metalloproteinases, the 'Sheddases'. Semin Cell Dev Biol 2009; 20:138-145.
65. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med 2008; 29:258-289.
66. Terawaki S, Kitano K, Aoyama M, et al. MT1-MMP recognition by ERM proteins and its implication in CD44 shedding. Genes Cells 2015; 20:847-859.
67. Wong HS, Jaumouille V, Heit B, et al. Cytoskeletal confinement of CX3CL1 limits its susceptibility to proteolytic cleavage by ADAM10. Mol Biol Cell 2014; 25:3884-3899.
68. Aimes RT, Zijlstra A, Hooper JD, et al. Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis. Thromb Haemost 2003; 89:561-572.
69. Driesbaugh KH, Buzza MS, Martin EW, et al. Proteolytic activation of the protease-activated receptor (PAR)-2 by the glycosylphosphatidylinositol-anchored serine protease testisin. J Biol Chem 2015; 290:3529-3541.
70. Awasthi V, Mandal SK, Papanna V, et al. Modulation of tissue factor-factor VIIa signaling by lipid rafts and caveolae. Arterioscler Thromb Vasc Biol 2007; 27:1447-1455.
71. Bae JS, Yang L, Rezaie AR. Lipid raft localization regulates the cleavage specificity of protease activated receptor 1 in endothelial cells. J Thromb Haemost 2008; 6:954-961.
72. Wallez Y, Huber P. Endothelial adherens and tight junctions in vascular homeostasis, inflammation and angiogenesis. Biochim Biophys Acta 2008; 1778:794-809.
73. McCaffrey G, Staatz WD, Quigley CA, et al. Tight junctions contain oligomeric protein assembly critical for maintaining blood-brain barrier integrity in vivo. J Neurochem 2007; 103:2540-2555.
74. Koenen RR, Pruessmeyer J, Soehnlein O, et al. Regulated release and functional modulation of junctional adhesion molecule A by disintegrin metalloproteinases. Blood 2009; 113:4799-4809.
75. Sun C, Wu MH, Guo M, et al. ADAM15 regulates endothelial permeability and neutrophil migration via Src/ERK1/2 signalling. Cardiovasc Res 2010; 87:348-355.
76. Chatterjee V, Beard RS Jr, Reynolds JJ, et al. MicroRNA-147b regulates vascular endothelial barrier function by targeting ADAM15 expression. PLoS One 2014; 9:e110286.
77. Tian X, Tian Y, Gawlak G, et al. Control of vascular permeability by atrial natriuretic peptide via a GEF-H1-dependent mechanism. J Biol Chem 2014; 289:5168-5183.
78. Simoes e Silva AC, Silveira KD, Ferreira AJ, et al. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol 2013; 169:477-492.
79. Zhang YH, Zhang YH, Dong XF, et al. ACE2 and Ang-(1-7) protect endothelial cell function and prevent early atherosclerosis by inhibiting inflammatory response. Inflamm Res 2015; 64:253-260.
80. Gallo S, Sala V, Gatti S, Crepaldi T. Cellular and molecular mechanisms of HGF/Met in the cardiovascular system. Clin Sci (Lond) 2015; 129:1173-1193.
81. Sahin U, Weskamp G, Kelly K, et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004; 164:769-779.
82. Peschon JJ, Slack JL, Reddy P, et al. An essential role for ectodomain shedding in mammalian development. Science 1998; 282:1281-1284.
83. Jackson LF, Qiu TH, Sunnarborg SW, et al. Defective valvulogenesis in HBEGF and TACE-null mice is associated with aberrant BMP signaling. EMBO J 2003; 22:2704-2716.
84. Ohtsu H, Dempsey PJ, Eguchi S. ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am J Physiol Cell Physiol 2006; 291:C1-C10.
85. Overland AC, Insel PA. Heterotrimeric G proteins directly regulate MMP14/membrane type-1 matrix metalloprotease: a novel mechanism for GPCREGFR transactivation. J Biol Chem 2015; 290:9941-9947.
86. Hiraoka N, Allen E, Apel IJ, et al. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 1998; 95:365-377.
87. Hotary KB, Yana I, Sabeh F, et al. Matrix metalloproteinases (MMPs) regulate fibrin-invasive activity via MT1-MMP-dependent and -independent processes. J Exp Med 2002; 195:295-308.
88. Kang H, Duran CL, Abbey CA, et al. Fluid shear stress promotes proprotein convertase-dependent activation of MT1-MMP. Biochem Biophys Res Commun 2015; 460:596-602.
89. Yana I, Sagara H, Takaki S, et al. Crosstalk between neovessels and mural cells directs the site-specific expression of MT1-MMP to endothelial tip cells. J Cell Sci 2007; 120:1607-1614.
90. Itoh Y, Takamura A, Ito N, et al. Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J 2001; 20:4782-4793.
91. Otto S, Deussen A, Zatschler B, et al. A novel role of endothelium in activation of latent pro-membrane type 1 matrix metalloproteinase and pro-matrix metalloproteinase-2 in rat aorta. Cardiovasc Res 2015. [Epub ahead of print]
92. Buache E, Thai R, Wendling C, et al. Functional relationship between matrix metalloproteinase-11 and matrix metalloproteinase-14. Cancer Med 2014; 3:1197-1210.
93. Noel A, Maillard C, Rocks N, et al. Membrane associated proteases and their inhibitors in tumour angiogenesis. J Clin Pathol 2004; 57:577-584.
94. White SJ, Hayes EM, Lehoux S, et al. Characterization of the differential response of endothelial cells exposed to normal and elevated laminar shear stress. J Cell Physiol 2011; 226:2841-2848.
95. Fukushima Y, Okada M, Kataoka H, et al. Sema3E-PlexinD1 signaling selectively suppresses disoriented angiogenesis in ischemic retinopathy in mice. J Clin Invest 2011; 121:1974-1985.
96. Tugues S, Morales-Ruiz M, Fernandez-Varo G, et al. Microarray analysis of endothelial differentially expressed genes in liver of cirrhotic rats. Gastroenterology 2005; 129:1686-1695.
97. Strasser GA, Kaminker JS, Tessier-Lavigne M. Microarray analysis of retinal endothelial tip cells identifies CXCR4 as a mediator of tip cell morphology and branching. Blood 2010; 115:5102-5110.
98. Glesne DA, Zhang W, Mandava S, et al. Subtractive transcriptomics: establishing polarity drives in vitro human endothelial morphogenesis. Cancer Res 2006; 66:4030-4040.
99. Piltonen TT, Chen J, Erikson DW, et al. Mesenchymal stem/progenitors and other endometrial cell types from women with polycystic ovary syndrome (PCOS) display inflammatory and oncogenic potential. J Clin Endocrinol Metab 2013; 98:3765-3775.